AbbVie has unveiled the first data from its $350 million obesity bet, with the amylin...
AbbVie
AbbVie has made no secret of the fact that it’s taken an interest in the...
AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a...
Close to two years after AbbVie handed over $48 million for the rights to Ose...
AbbVie is opening submissions for an award that will provide one Canadian biotech with free...
AbbVie has scrapped an asset from its ongoing collaboration with Dragonfly Therapeutics, a spokesperson for...
With a new approach to creating thymus-targeted medicines for autoimmune diseases, Zag Bio has emerged...
AbbVie has written the next chapter in its epic quest to treat psychiatric disorders, agreeing to...
AbbVie is acquiring its second trispecific T cell-engaging antibody that is in early-stage trials for...
AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC)...